Clinical Trial Update: Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing rivaroxaban to aspirin for secondary prevention after embolic stroke of undetermined source (ESUS); study terminated with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stroke

Drugs mentioned

• Aspirin (Aspirin)
• Rivaroxaban (rivaroxaban)

Snippet

Sponsor: Bayer | Conditions: Stroke | Phase 3 | Status: TERMINATED | Results posted: 2019-01-09